Stockscreener 앱 받기
2.40
2.04%
-0.05
전일 마감가:
$2.45
열려 있는:
$2.45
하루 거래량:
35,479
Relative Volume:
0.19
시가총액:
$3.81M
수익:
$72,100
순이익/손실:
$-4.84M
주가수익비율:
-0.3219
EPS:
-7.4566
순현금흐름:
$-3.84M
1주 성능:
-5.51%
1개월 성능:
-47.83%
6개월 성능:
-55.54%
1년 성능:
-73.36%
1일 변동 폭
$2.205
$2.50
1주일 범위
$2.205
$2.56
52주 변동 폭
$2.205
$15.15
Silo Pharma Inc Stock (SILO) Company Profile
명칭
Silo Pharma Inc
전화
(718) 400-9031
주소
677 N. WASHINGTON BLVD, SARASOTA
Compare SILO vs PSNYW, GOODO, SHMD, DWLD, QQQE
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
5.00 | 394.14M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.92 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
3.15 | 315.90M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.39 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
120.75 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc 주식(SILO)의 최신 뉴스
Form 8K Silo Pharma Inc For: 19 August By Investing.com - Investing.com South Africa
Silo Pharma Acquires Digital Assets via Stock Issuance - TipRanks
Silo Pharma Acquires Software and IP From Parkview Consulting for 165,000 Shares - TradingView
Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting - TradingView
Silo Pharma Secures Canadian Patent Allowance for PTSD Treatment SPC-15 - citybuzz -
Silo Pharma receives Canadian patent allowance for SPC-15 drug By Investing.com - Investing.com Canada
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment - The Manila Times
A PTSD treatment designed to build stress resilience gets Canadian patent allowance - Stock Titan
Silo (SILO) Technical Check: Adds 1.95% to Close at $3.13; Range and Risk: the $2.97 to $3.29 Range Remains in Focus in the Current UpdateSuperTrend - Vinanet
Silo Pharma Shareholders Approve Major Share Authorization Expansion - TipRanks
Silo Pharma (SILO) holders approve lifting share cap from 6.7M - Stock Titan
Silo Pharma (SILO) Slips 0.62% to $3.20 as Shares Consolidate Between Key Technical LevelsStock Picks - Vinanet
Silo Pharma (SILO) trims cash burn, mitigates going-concern risk in Q2 2026 - Stock Titan
Silo Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Silo Pharma (SILO) investor group discloses 9.99% warrant-based ownership cap - Stock Titan
Silo Pharma receives European patent for SPC-15 PTSD treatment By Investing.com - Investing.com South Africa
Silo Pharma Granted European Patent Covering Novel PTSD Therapy - The Manila Times
Silo Pharma receives European patent for SPC-15 PTSD treatment - Investing.com India
Silo Pharma Announces European Patent Grant for SPC-15 PTSD Prevention Therapy - Quiver Quantitative
SILO Q4 2023 Earnings: EPS Misses Estimates, Stock Gains 1.2% Despite No RevenueCore Business Growth - vinanet.vn
Silo Pharma Inc (SILO) Stock News Today - TradingKey
Silo Pharma Inc (SILO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Silo Pharma, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Silo Pharma (SILO) Q4 2023 Earnings: Wider-Than-Expected Loss Sends Shares Down 20%Trough Earnings Signal - dars.gov.et
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform - marketscreener.com
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon - GlobeNewswire
Silo Pharma's QwikAgents partners with AWS expe... - Pluang
SILO|Silo Pharma Inc|Price:3.200|Chg%:-0.020 - TradingKey
Silo Pharma Inc (NASDAQ: SILO) Share Price, SILO Stock News, SILO Share Price & Updates - Kalkine
SILO Q4 2023 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage R&D SpendingQuarterly Earnings Report - Vinanet
Silo Pharma, Inc. Revenue Breakdown – NASDAQ:SILO - TradingView
Silo Pharma Inc (SILO) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
Silo Pharma Inc. Q4 2023 Earnings: Wider-Than-Expected Loss Weighs on SharesProfit Warning Alert - dars.gov.et
Silo Pharma Inc (SILO) Income Statement - TradingKey
SILO|Silo Pharma Inc|Price:4.470|Chg%:+0.010 - TradingKey
Silo Pharma Inc (SILO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Silo Pharma Inc (SILO) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Form S-3 Silo Pharma Inc For: 24 July By Investing.com - Investing.com India
Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common StockSEC Filing - TradingView
SILO Q4 2023 Earnings: Significant EPS Miss Highlights Operational ChallengesEarnings Volatility Report - vinanet.vn
Silo Pharma Advances AI Agent Platform Toward Commercial Launch And Progresses Lead PTSD Drug Program SPC-15 - marketscreener.com
Silo Pharma plans AI platform launch, advances PTSD drug program By Investing.com - Investing.com Canada
Silo Pharma Advances QwikAgents Commercial Launch and SPC-15 Development - Quiver Quantitative
Silo Pharma expects its PTSD nasal-spray study to finish in 60 days - Stock Titan
Silo Pharma raises $4 million in private placement By Investing.com - Investing.com Nigeria
Silo Pharma, Inc. (SILO) Stock: Slide 4.92% as QwikAgents Joins AMD AI Developer Program - CoinCentral
Silo Pharma (SILO) Q4 2023 Earnings: EPS Misses by Wide Margin, No Revenue Reported; Stock Gains 1.89%Gross Profit Margin - po-news-eg.net
Silo Pharma unit eyes faster AI agent development through AMD partnership - MSN
Silo Pharma Gains AI Spotlight After NVIDIA Partnership Enhances QwikAgents PlatformAdjusted Earnings Analysis - dars.gov.et
Silo Pharma (SILO) completes $4,000,015 private exempt securities sale - Stock Titan
Silo Pharma Inc (SILO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Silo Pharma Inc 주식 (SILO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | Chief Executive Officer |
Nov 20 '25 |
Buy |
0.37 |
1,000 |
370 |
210,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 21 '25 |
Buy |
0.36 |
1,000 |
365 |
211,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 18 '25 |
Buy |
0.40 |
7,500 |
3,025 |
205,432 |
| Weisblum Eric | Chief Executive Officer |
Nov 19 '25 |
Buy |
0.41 |
4,500 |
1,823 |
209,932 |
0.86%
0.31%
자본화:
|
볼륨(24시간):